|
Feb 19
|
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
|
|
Feb 18
|
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
|
|
Feb 18
|
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
|
|
Feb 18
|
Biogen buys rights to Stoke’s rare epilepsy drug
|
|
Jul 28
|
The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%
|
|
Jun 18
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
|
May 22
|
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
|
|
May 8
|
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
|
|
May 7
|
Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 6
|
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 6
|
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
|
|
Apr 29
|
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
|
|
Apr 29
|
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
|
|
Apr 25
|
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
|
|
Apr 17
|
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
|
|
Apr 4
|
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 28
|
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
|
|
Mar 27
|
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
|
|
Mar 26
|
Stoke Therapeutics Announces Proposed Public Offering
|
|
Mar 26
|
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
|